Table 2.
Summary of pharmacoactive and bioactive carrier systems (PBACS)
| Name | API | Active Carrier | Carrier Activity | Size (nm) | Indication | Efficacy | API Loading (w/w%) |
Ref |
|---|---|---|---|---|---|---|---|---|
| DHFR-bisMTX CSANs | DHFR2a ntiCD3 | bisMTX | CD3+ trafficking | 280–494 | CD3+ T- leukemia cells |
↑ 13X cytotoxicity | N/A | [63] |
| RNAi-DOX-DNA | DOX | DNA, RNAi, aptamer |
Anti-MDR gene therapy | N/A | MCF-7R tumor | ↑ 4 tumor inhibition | N/A | [64] |
| CXCR4-scFv-RBM | miRNA | CXCR4-scFv | Macrophage polarization | 113–119 | 4T1 tumor | ↑ 2X tumor inhibition | 90 | [65] |
| HA-PTX-Caspase 3 | PTX | Caspase 3 and HA | Apoptosis | 160 | MCF-7 | ↑ 1.5X accumulation, ↑ 7X caspase 3 |
N/A | [66] |
| siRNA-Aptamer NPrs | Rab26 siRNA | MUC-1 | Apoptosis | 14–21 | A549, H1299 cells |
↑ 9.1X cell internalization | N/A | [67] |
| DNA NTs | DNA | DNA | miRNA knockdown | 22.4 | H1299, MCF-7 | ↑ 15X cellular uptake | N/A | [68] |
| RNA micelles | PTX | RNA | Apoptosis | 104–133 | KB cells | ↑ 8.1X cancer cell apoptosis | N/A | [69] |
| DOX-siRNA NA | DOX | siRNA | ICD | 25–45 | CT26 cells | ↑ 0.48X tumor inhibition | 21.67 | [70] |
| UA-DOX NPs | DOX | UA, Aptamer | Anti-metastasis | 108.9 | BT474 cells | ↑ 2X drug retention | 99.6 | [71] |
| DOX-Aptamer | DOX | Aptamer | Antiproliferation | 9- 11.6 |
Anti-PC3, 4T1 cells | ↑ 1.99X tumor inhibition | N/A | [72] |
| VES-Ir NPs | Ir | VES | Apoptosis | 75.4 | MCF-7, A549 | ↑ 1.86X tumor inhibition | 100 | [73] |
| MTX-MAN NPs | MTX | Mannose | Apoptosis | 100 | MCF-7 | ↑ 1.4X tumor inhibition | N/A | [74] |
†
NPrs: nanoprisms; NTs: nanotubes; NA: nanoassembly; NPs: nanoparticles